Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ZNF384
REST API REST API
Homo sapiens
ZNF384 is differentially expressed in 189 experiments: 94 organism parts: cerebellum, liver, ... (92 more);, 106 disease states: normal, acute lymphoblastic leukemia, ... (104 more);, 50 cell types 233 cell lines 22 compound treatments and 60 other conditions.
Synonyms NP, NMP4, CAGH1A, CIZ, TNRC1
Orthologs ZNF384 (2 of 3) (Danio rerio)   Q5ZM27_CHICK (Gallus gallus)   ENSCING00000007055 (Ciona intestinalis)   ZNF384 (3 of 3) (Danio rerio)   znf384l (Danio rerio)   Zfp384 (Mus musculus)   A9X431_BOVIN (Bos taurus)   Zfp384 (Rattus norvegicus)   znf384 (Xenopus laevis)   ZNF384 (Canis familiaris)   Lin29 (Drosophila melanogaster)   (Compare orthologs)
Gene Ontology Term focal adhesion, DNA binding, regulation of transcription, DNA-dependent, intracellular, SH3 domain binding, metal ion binding, nucleic acid binding, nucleus, nucleocytoplasmic transport, zinc ion binding
InterPro Term Znf_C2H2-like, Znf_C2H2
UniProt Accession A9X425, A9X424, Q8TF68, D3DUR9, B4DQU6, F5H8L7, F5GYZ1, E9PHB3, F5H105, F5H0D6, F5H6N8, F5H4M1, F5H3Z9, F5H420, F8W6Q3
Search EB-eye ENSG00000126746
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, ... (20 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, E-GEOD-4717, ... (34 experiments)

Factor Value U/D Experiments
BT-474
2
E-GEOD-3529, E-GEOD-5823
MCF-7
2
E-GEOD-19639, E-GEOD-20081
MDA468
2
E-MEXP-440, E-MTAB-62
NA19098
1
E-GEOD-19480
HuT78
1
E-MTAB-37
SKNFI
1
E-MTAB-37
227 more value(s).


Cell type

studied in E-GEOD-20677, E-GEOD-13909, E-GEOD-4219, E-GEOD-13987, E-GEOD-21750, ... (30 experiments)

Factor Value U/D Experiments
memory B cell
1
E-MEXP-2360
adult native RPE from 78 y.o. donor
1
E-GEOD-18811
bronchial epithelial
1
E-AFMX-5
monolayer recovery
1
E-GEOD-4219
CXCR4 negative
1
E-GEOD-15893
immortalised T lymphocytes
1
E-GEOD-13909
44 more value(s).


Disease state

studied in E-GEOD-6872, E-MEXP-25, E-GEOD-1577, E-GEOD-20602, E-MTAB-62, ... (36 experiments)

Factor Value U/D Experiments
rhabdomyosarcoma
2
E-MTAB-62, E-MTAB-37
lung adenocarcinoma
2
E-GEOD-2514, E-MTAB-37
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
acute lymphoblastic leukemia
1
2
E-MTAB-62, E-MTAB-37, E-GEOD-96
acute lymphocytic leukemia
1
E-GEOD-1880
liposarcoma
1
E-MTAB-37
100 more value(s).


Compound treatment

studied in E-GEOD-571, E-GEOD-5258, E-GEOD-6907, E-GEOD-5824, E-GEOD-5099, ... (15 experiments)

Factor Value U/D Experiments
none
1
3
E-GEOD-5824, E-GEOD-412, E-GEOD-5099, E-GEOD-1740
control
2
E-GEOD-3284, E-GEOD-5339
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
control for EGF
1
E-GEOD-6462
unknown
1
E-GEOD-7307
mercaptopurine, methotrexate
1
E-GEOD-412
16 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-860, E-MEXP-1251, E-GEOD-21589 ... (5 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-3013

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-6431

Genotype
studied in E-GEOD-17476, E-GEOD-2292, E-TABM-321, E-GEOD-1153, E-GEOD-17347 ... (5 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-MEXP-2657, E-MEXP-1446, E-GEOD-10315, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-1432, E-MEXP-2069, E-GEOD-1926, ... (23 experiments)

Infection
studied in E-GEOD-12108

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-17636

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19246, E-GEOD-1343

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561

Vehicle
studied in E-GEOD-5258

Processing time: 0.392 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM